Frédéric Spagnoli

  • Citations Per Year
Learn More
BACKGROUND AND PURPOSE Erythropoietin (EPO) has been demonstrated to possess significant neuroprotective effects in stroke. We determined if the nano-drug form of human recombinant EPO (PLGA-EPO nanoparticles [PLGA-EPO-NP]) can enhance neuroprotection at lower dosages versus human recombinant EPO (r-EPO). METHODS Established neonatal rat model of(More)
  • 1